Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
暂无分享,去创建一个
M. Namer | J. Bonneterre | M. Campone | A. Monnier | P. Romestaing | P. Fargeot | P. Kerbrat | P. Montcuquet | É. Luporsi | H. Roché
[1] R. Theriault. Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone as Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-up Results of the French Adjuvant Study Group 08 Trial , 2005 .
[2] S. Schraub,et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] N. Wolmark,et al. Adjuvant tamoxifen and chemotherapy in stage II breast cancer: Interim findings from NSABP protocol B-09 , 1985, World Journal of Surgery.
[4] N. Wolmark,et al. Adjuvant chemotherapy in stage II breast cancer: A brief overview of the NSABP clinical trials , 1985, World Journal of Surgery.
[5] H. Mouridsen,et al. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer , 1983, Breast Cancer Research and Treatment.
[6] G. Bonadonna,et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer , 2005, Breast Cancer Research and Treatment.
[7] W. McGuire,et al. Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: Five-year results , 2005, Breast Cancer Research and Treatment.
[8] L. Schwartzberg,et al. Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Tres,et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] S. Schraub,et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Cavalli,et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Coombes,et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[15] G. Ribeiro,et al. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma--7-yr results. , 1985, European journal of cancer & clinical oncology.
[16] L. Kalish,et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Rasmussen,et al. BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES , 1985, The Lancet.
[18] RANDOMISED TRIAL OF CHEMO-ENDOCRINE THERAPY, ENDOCRINE THERAPY, AND MASTECTOMY ALONE IN POSTMENOPAUSAL PATIENTS WITH OPERABLE BREAST CANCER AND AXILLARY NODE METASTASIS Ludwig Breast Cancer Study Group , 1984, The Lancet.
[19] R. K. Knight,et al. CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER , 1983, The Lancet.
[20] H. Mouridsen,et al. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. , 1980, European journal of cancer.
[21] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[23] D.,et al. Regression Models and Life-Tables , 2022 .